A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered ALS-008176 Regimens in Adult Subjects Hospitalized with Respiratory Syncytial Virus
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Lumicitabine (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacokinetics
- Sponsors Janssen Pharmaceutical KK; Janssen Research & Development
Most Recent Events
- 19 Oct 2018 Status changed from suspended to discontinued.
- 19 Jul 2018 Status changed from recruiting to suspended.
- 11 Jul 2018 This trial has been Suspended in Sweden, according to European Clinical Trials Database